A phase II multicenter study to assessed safety and tolerability of PARI Tobramycin 100 administered via an Investigational eFlow Nebulizer System in comparison to TOBI delivered via the PARI LC PLUS in patients suffering from cystic fibrosis

Trial Profile

A phase II multicenter study to assessed safety and tolerability of PARI Tobramycin 100 administered via an Investigational eFlow Nebulizer System in comparison to TOBI delivered via the PARI LC PLUS in patients suffering from cystic fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top